China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging its DNA Encoded Library (DEL) technology to screen compounds for targets identified by LoQus23. The collaboration aims to develop small-molecule drugs targeting DNA mismatch repair (MMR) to slow neurodegeneration in diseases like Huntington’s and myotonic dystrophy type 1.
Partnership Details
LoQus23 focuses on developing small-molecule drugs that target DNA MMR to prevent DNA instability and slow neurodegeneration. HitGen will use its DEL technology to screen compounds that can bind to the targets identified by LoQus23.
HitGen’s Technology Platform
HitGen specializes in RNAi drug discovery and optimization, with a core technology platform that integrates the entire technology chain, including RNA sequence design, synthesis, off-target effect prediction, and biological function evaluation. The company’s DNA-encoded compound library contains over 1.2 trillion small-molecule types, making it the largest and most diverse library of its kind globally.-Fineline Info & Tech
